Supplementary Table 2.
Study details of the three post-hoc analysis data of the study done by Frias et al. (2018) evaluated in this meta-analysis
| Study details | Number of patients in tirzepatide and control groups | Patient characteristics and nature of controls | Duration of study (weeks) | Outcomes evaluated in the study and reasons for exclusion |
|---|---|---|---|---|
| Wilson et al.[6] | Placebo 51 Tirzepatide 1 mg, 52 patients Tirzepatide 5 mg, 55 patients Tirzepatide 10 mg, 51 patients Tirzepatide 15 mg, 53 patients Dulaglutide 1.5 mg, 54 patients |
People with type 2 diabetes for at least 6 months WITH inadequately controlled diabetes on diet, exercise±metformin AND body mass index (BMI) of 23-50 kg.m2
Controls (in Dulaglutide or placebo) were similar to subjects in Tirzepatide group |
26 weeks | Change in serum lipoprotein profile, apolipoprotein (apo) A-I, B and C-III and preheparin lipoprotein lipase from baseline to at 4, 12, and 26 weeks; change in lipoprotein particle profile at baseline and 26 weeks |
| Hartmen et al.[18] | Placebo 51 Tirzepatide 1 mg 52 Tirzepatide 5 mg 55 Tirzepatide 10 mg 51 Tirzepatide 15 mg 53 Dulaglutide 1.5 mg 54 |
People with type 2 diabetes for at least 6 months WITH inadequately controlled diabetes on diet, exercise±metformin AND body mass index (BMI) of 23-50 kg.m2
Controls (in Dulaglutide or placebo) were similar to subjects in Tirzepatide group. |
26 weeks | Changes from baseline in alanine aminotransferase (ALT), aspartate aminotransferase (AST), keratin-18 (K-18), procollagen III (Pro-C3), and adiponectin |
| Thomas et al.[19] | Placebo 51 Tirzepatide 1 mg, 52 patients Tirzepatide 5 mg, 55 patients Tirzepatide 10 mg, 51 patients Tirzepatide 15 mg, 53 patients Dulaglutide 1.5 mg, 54 patients |
People with type 2 diabetes for at least 6 months WITH inadequately controlled diabetes on diet, exercise±metformin AND body mass index (BMI) of 23-50 kg.m2
Controls (in Dulaglutide or placebo) were similar to subjects in Tirzepatide group |
26 weeks | Change in biomarkers of beta-cell function and insulin resistance (IR) and evaluate weight loss contributions to IR improvements at 26 weeks |
| Pirro et al.[20] | Placebo 51 Tirzepatide 1 mg, 52 patients Tirzepatide 5 mg, 55 patients Tirzepatide 10 mg, 51 patients Tirzepatide 15 mg, 53 patients Dulaglutide 1.5 mg, 54 patients |
People with type 2 diabetes for at least 6 months WITH inadequately controlled diabetes on diet, exercise±metformin AND body mass index (BMI) of 23-50 kg.m2
Controls (in Dulaglutide or placebo) were similar to subjects in Tirzepatide group |
26 weeks | Branched-chain amino acids, direct catabolic products glutamate, 3-hydroxyisobutyrate, branched-chain ketoacids, and indirect byproducts such as 2-hydroxybutyrate decreased compared to baseline and placebo. The decrease in the above metabolites was greater in the Tirzepatide group as compared to dulaglutide |
T2DM: type-2 diabetes; OAD: oral antidiabetes medication; GFR: glomerular filtration rate